Amgen enters agreement to develop outcomes-based contracts

Amgen has sealed an agreement with Inovalon, a specialist in health data analytics, to develop outcomes based contracts based on the value of Amgen’s products.

The agreement will focus specifically on rheumatoid arthritis, a chronic, high-cost autoimmune disease affecting more than two million Americans. As the healthcare landscape continues to rapidly transform from fee-for-service and volume-based models, to value and outcomes-based models, outcomes-based contracts have become increasingly prevalent in the marketplace.

Inovalon’s outcomes-based contracting platform supports the creation, deployment and management of value-based contracts between payers and life sciences companies, using data aggregation and management, predictive analytics, data-driven patient and provider engagement platforms, and data reporting capabilities.



Related Articles

UK New Cambridge research institute wants to cure hospital inefficiency

The science of healthcare is underdeveloped. A first-in-Europe institute opening in Cambridge aims to change this, providing evidence of how to organise health to improve outcomes

4 April 2017

Setting the bar for measuring patient outcomes

ICHOM standards will soon cover half the global disease burden. Christina Åkerman, head of the consortium tells Science|Business their application will highlight inequalities, give greater priority to quality of life and help healthcare systems extract more value from restricted budgets

4 April 2017